AI-guided Antibiotic Discovery Pipeline from Target Selection to Compound Identification
By: Maximilian G. Schuh, Joshua Hesse, Stephan A. Sieber
Potential Business Impact:
Finds new medicines to fight superbugs.
Antibiotic resistance presents a growing global health crisis, demanding new therapeutic strategies that target novel bacterial mechanisms. Recent advances in protein structure prediction and machine learning-driven molecule generation offer a promising opportunity to accelerate drug discovery. However, practical guidance on selecting and integrating these models into real-world pipelines remains limited. In this study, we develop an end-to-end, artificial intelligence-guided antibiotic discovery pipeline that spans target identification to compound realization. We leverage structure-based clustering across predicted proteomes of multiple pathogens to identify conserved, essential, and non-human-homologous targets. We then systematically evaluate six leading 3D-structure-aware generative models$\unicode{x2014}$spanning diffusion, autoregressive, graph neural network, and language model architectures$\unicode{x2014}$on their usability, chemical validity, and biological relevance. Rigorous post-processing filters and commercial analogue searches reduce over 100 000 generated compounds to a focused, synthesizable set. Our results highlight DeepBlock and TamGen as top performers across diverse criteria, while also revealing critical trade-offs between model complexity, usability, and output quality. This work provides a comparative benchmark and blueprint for deploying artificial intelligence in early-stage antibiotic development.
Similar Papers
Accelerating Antibiotic Discovery with Large Language Models and Knowledge Graphs
Computation and Language
Finds new medicines faster, avoids old ones.
A deep reinforcement learning platform for antibiotic discovery
Machine Learning (CS)
Creates new medicines to fight superbugs.
Can AI Agents Design and Implement Drug Discovery Pipelines?
Artificial Intelligence
AI finds new medicines faster than people.